Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple threat: new drug cocktail targets BRCA breast cancer

NCT ID NCT03685331

Completed Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tested a combination of three drugs—olaparib, palbociclib, and fulvestrant—in 9 people with BRCA-mutated, hormone-positive, HER2-negative metastatic breast cancer. The main goal was to see if the combination is safe. Researchers also looked at how long the cancer stayed under control and whether tumors shrank. Because the trial is very small and early, the results are preliminary and need further study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
olaparib, palbociclib, and fulvestrant (three drugs combined)
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for people with BRCA-mutated, hormone-positive metastatic breast cancer that has stopped responding to standard therapies.
What could go wrong
This is a very early, small Phase I/II trial with only 9 participants, so results may not apply to larger populations. The triple-drug combination may cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

BRCA1-related cancer predisposition BRCA2-related cancer predisposition breast cancer breast carcinoma breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER BRCA1 MUTATION BRCA2 MUTATION LOCALLY ADVANCED BREAST CANCER METASTATIC BREAST CANCER

Contacts and locations

Locations

  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.